what is the difference between cryptocurrency and digital currency- Top People searches

Saudi institutions are optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology. Ekta Torani, chief investment officer of Saudi KBW Venture Capital Company, recently said in Abu Dhabi, United Arab Emirates that with the increasingly close economic and trade ties between the Gulf region and China, the institution is optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology.Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.Hailide: PPS filament products have not yet been involved in the field of humanoid robots. Hailide said on the interactive platform on December 13th that the company has been deeply involved in the field of materials for many years, and with the continuous investment in research and development, the commercialization of PPS filament has been realized. At present, the product has not yet been involved in the field of humanoid robots. In the future, the company will strive to gradually realize mass production applications in related emerging fields, and is full of confidence in this.

On the 13th, the No.20 rubber fell by 2.05%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract No.20 rubber 2502 was closed, with a turnover of 159,100 lots. The position data showed that the top 20 seats were clear, and the difference position was 5,142 lots. A total of 205,200 lots were traded in the No.20 rubber futures contract, an increase of 8,176 lots over the previous day. The first 20 seats in the contract held 84,200 lots, an increase of 812 lots over the previous day. Short positions in the top 20 seats of the contract were 94,500 lots, a decrease of 1,708 lots from the previous day. (Sina Futures)Hunan procuratorate prosecuted Wang Yonghong for alleged bribery and abuse of power according to law. Recently, the case of Wang Yonghong (deputy department level), former member of the Standing Committee of Shaoyang Municipal Committee of Hunan Province and former executive deputy mayor of the Municipal People's Government, was assigned jurisdiction by Hunan Provincial People's Procuratorate, and Loudi Municipal People's Procuratorate prosecuted Loudi Intermediate People's Court according to law. The case is being further processed. At the stage of examination and prosecution, the procuratorial organ informed the defendant Wang Yonghong of his litigation rights according to law, interrogated the defendant according to law and listened to the opinions of defenders. Loudi City People's Procuratorate sued the accusation that the defendant Wang Yonghong, as a national staff member, used his position to seek benefits for others and illegally accepted other people's property, with a huge amount; As a staff member of a state organ, he abuses his power, causing great losses to the interests of the state and the people. According to law, he should be investigated for criminal responsibility for accepting bribes and abusing his power.Hunan procuratorate prosecuted Wang Yonghong for alleged bribery and abuse of power according to law. Recently, the case of Wang Yonghong (deputy department level), former member of the Standing Committee of Shaoyang Municipal Committee of Hunan Province and former executive deputy mayor of the Municipal People's Government, was assigned jurisdiction by Hunan Provincial People's Procuratorate, and Loudi Municipal People's Procuratorate prosecuted Loudi Intermediate People's Court according to law. The case is being further processed. At the stage of examination and prosecution, the procuratorial organ informed the defendant Wang Yonghong of his litigation rights according to law, interrogated the defendant according to law and listened to the opinions of defenders. Loudi City People's Procuratorate sued the accusation that the defendant Wang Yonghong, as a national staff member, used his position to seek benefits for others and illegally accepted other people's property, with a huge amount; As a staff member of a state organ, he abuses his power, causing great losses to the interests of the state and the people. According to law, he should be investigated for criminal responsibility for accepting bribes and abusing his power.

FTSE China A50 index futures fell 2%.Wuzhong, Jiangsu; Dobutamine Hydrochloride Injection and Paramivir Injection are planned to win the bid for the national centralized drug procurement. Jiangsu Wuzhong announced that in the national centralized drug procurement, the bid price of Dobutamine Hydrochloride Injection and Paramivir Injection is 3.58 yuan and 7.47 yuan respectively. The procurement cycle of the two products is until December 31, 2027, and they are supplied to Fujian, Anhui, Jilin, Hubei, Beijing, Inner Mongolia and other provinces and cities respectively. Winning the bid will help to expand the sales of related products, improve market share and brand influence, and have a positive impact on the company's future business performance.Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.